Next Article in Journal
Continuous Positive Airway Pressure Treatment in Patients with Alzheimer’s Disease: A Systematic Review
Next Article in Special Issue
The Complex Balance between Analgesic Efficacy, Change of Dose and Safety Profile Over Time, in Cancer Patients Treated with Opioids: Providing the Clinicians with an Evaluation Tool
Previous Article in Journal
Sensitivity to Experiencing Alcohol Hangovers: Reconsideration of the 0.11% Blood Alcohol Concentration (BAC) Threshold for Having a Hangover
Previous Article in Special Issue
Changes in Opioid Prescribing Behaviors among Family Physicians Who Participated in a Weekly Tele-Mentoring Program

Genome-Wide Association Study of Opioid Cessation

Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA 02118, USA
Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
Department of Psychiatry, Washington University in St. Louis, St. Louis, MO 63130, USA
School of Psychology, The University of Queensland, St Lucia QLD 4072, Australia
School of Medicine, University of New South Wales, Sydney NSW 2052, Australia
Perelman School of Medicine, University of Pennsylvania and VISN 4 MIRECC, Crescenz VAMC, Philadelphia, PA 19104, USA
Departments of Psychiatry, Genetics and Neuroscience, Yale School of Medicine, New Haven, CT 06511, USA
Department of Psychiatry, VA CT Healthcare Center, West Haven, CT 06516, USA
Departments of Neurology, Ophthalmology and Epidemiology, Boston University Schools of Medicine and Public Health, Boston, MA 02118, USA
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(1), 180;
Received: 9 December 2019 / Revised: 20 December 2019 / Accepted: 3 January 2020 / Published: 9 January 2020
(This article belongs to the Special Issue Application of Opioids in Clinical Medicine)
The United States is experiencing an epidemic of opioid use disorder (OUD) and overdose-related deaths. However, the genetic basis for the ability to discontinue opioid use has not been investigated. We performed a genome-wide association study (GWAS) of opioid cessation (defined as abstinence from illicit opioids for >1 year or <6 months before the interview date) in 1130 African American (AA) and 2919 European ancestry (EA) participants recruited for genetic studies of substance use disorders and who met lifetime Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for OUD. Association tests performed separately within each ethnic group were combined by meta-analysis with results obtained from the Comorbidity and Trauma Study. Although there were no genome-wide significant associations, we found suggestive associations with nine independent loci, including three which are biologically relevant: rs4740988 in PTPRD (pAA + EA = 2.24 × 10−6), rs36098404 in MYOM2 (pEA = 2.24 × 10−6), and rs592026 in SNAP25-AS1 (pEA = 6.53 × 10−6). Significant pathways identified in persons of European ancestry (EA) are related to vitamin D metabolism (p = 3.79 × 10−2) and fibroblast growth factor (FGF) signaling (p = 2.39 × 10−2). UK Biobank traits including smoking and drinking cessation and chronic back pain were significantly associated with opioid cessation using GWAS-derived polygenic risk scores. These results provide evidence for genetic influences on opioid cessation, suggest genetic overlap with other relevant traits, and may indicate potential novel therapeutic targets for OUD. View Full-Text
Keywords: genome-wide association study; opioid cessation; opioid use disorder; shared genetic risk; polygenic risk score genome-wide association study; opioid cessation; opioid use disorder; shared genetic risk; polygenic risk score
MDPI and ACS Style

Cox, J.W.; Sherva, R.M.; Lunetta, K.L.; Johnson, E.C.; Martin, N.G.; Degenhardt, L.; Agrawal, A.; Nelson, E.C.; Kranzler, H.R.; Gelernter, J.; Farrer, L.A. Genome-Wide Association Study of Opioid Cessation. J. Clin. Med. 2020, 9, 180.

AMA Style

Cox JW, Sherva RM, Lunetta KL, Johnson EC, Martin NG, Degenhardt L, Agrawal A, Nelson EC, Kranzler HR, Gelernter J, Farrer LA. Genome-Wide Association Study of Opioid Cessation. Journal of Clinical Medicine. 2020; 9(1):180.

Chicago/Turabian Style

Cox, Jiayi W., Richard M. Sherva, Kathryn L. Lunetta, Emma C. Johnson, Nicholas G. Martin, Louisa Degenhardt, Arpana Agrawal, Elliot C. Nelson, Henry R. Kranzler, Joel Gelernter, and Lindsay A. Farrer. 2020. "Genome-Wide Association Study of Opioid Cessation" Journal of Clinical Medicine 9, no. 1: 180.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop